Brief: Cambium Bio Says FDA Approves Potency Assay Strategy
18/03/2025 24:51
March 18 (Reuters) - Cambium Bio Ltd CMB.AX: FDA APPROVES CAMBIUM BIO'S POTENCY ASSAY STRATEGY FOR ELATE OCULAR PHASE 3 CLINICAL TRIALS Further company coverage: CMB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cambium Bio
See all newsAustralia's Cambium Bio hits near three-month high on share placement at premium
Brief: Cambium Bio Appoints Olga Smejkalova As Company Secretary
Australia's Cambium Bio gains after premium share placement
Brief: Cambium Bio Raises A$1 MLN At A$0.48 Per Share
Brief: Cambium Bio Receives A$2.4 Million Investment From Zheng Yang Biomedical Technology